Neurolieve Biosciences

Neurolieve Biosciences is a pioneering biotech company focused on developing innovative therapies for neuropathic pain, a complex and multifaceted health challenge caused by conditions such as diabetes and chemotherapy. The company is currently in the preclinical stage, having achieved promising results in both in vitro and in vivo studies using various rodent disease models. Neurolieve Biosciences aims to advance to First-In-Human (FIH) studies following the completion of GLP toxicology studies. The company primarily serves patients suffering from peripheral neuropathy, which significantly impacts daily life by causing fatigue, poor sleep, and memory disturbances. The business operates within the biotech and pharmaceutical market, targeting a niche segment with high unmet medical needs. Neurolieve Biosciences generates revenue through the development and potential commercialization of its therapeutic solutions, as well as through partnerships and collaborations with larger pharmaceutical companies.

Keywords: neuropathic pain, preclinical research, rodent models, peripheral neuropathy, biotech, pharmaceutical, GLP toxicology, FIH studies, innovative therapies, Massimo Mineo.